Immunogenecity and safety of heat-inactivated hepatitis B vaccine (CLB) in low risk human volunteers and in patients treated with chronic haemodialysis in The Netherlands. E.E. Reerink-Brongers, P.N. Lelie, H.W. Reesink, P.J. Dees, H.G.J. Brummelhuis and W.G. van Aken. Dev-Biol Stand. 1983, 54: 197-203.
Overview of safety, immunogenicity and efficacy of heat-inactivated hepatitis B vaccine. H.W. Reesink, E.E. Reerink-Brongers, H.G.J. Brummelhuis, P.N. Lelie, P.J. Dees, B.Th. Visser and W.G. van Aken. Proceedings of 1984 International Symposium on Viral Hepatitis. Ed. G.N. Vyas, J.L. Dienstag and J.H. Hoofnagle. Grune & Stratton Inc. Orlando, 1984, 659.
Inactivation of the Hutchinson strain of non-A, non-B hepatitis virus by combined use of beta-propiolactone and ultraviolet irradiation. Prince AM, Stephan W, Dichtelmüller H, Brotman B, Huima T.J Med Virol. 1985 Jun;16(2):119-25.
Beta-propiolactone for the inactivation of non-A/non-B type 1 hepatitis virus capable of inducing cytoplasmic tubular ultrastructures in chimpanzees. Yoshizawa H, Itoh Y, Iwakiri S, Kitajima K, Noguchi Y, Tachibana K, Nakamura T, Miyakawa Y, Mayumi M. Vox Sang. 1984;46(2):86-91.
Inactivation of 10(15)chimpanzee infectious doses of hepatitis B virus during preparation of an heat-inactivated hepatitis B vaccine. P.N. Lelie, H.W. Reesink, J. Niessen, B. Brotman and A.M. Prince. J. Med. Virol. 1987 Nov, 23(3): 289-95
Inactivation of 12 viruses by heating steps appliec during manufacture of a hepatitis B vaccine. P.N. Lelie, H.W. Reesink and C.J. Lucas. J. Med. Virol. 1987 Nov, 23(3): 297-301.
Centers for Disease Control (CDC). Recommendations for prevention of HIV transmission in health care settings. MMWR 1987; 36 (supplement no. 2S).
Centers for Disease Control (CDC). Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 1988; 37:377-388.
Centers for Disease Control (CDC). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989; 38(S-6): 1-36.
Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins. Hilfenhaus JW, Gregersen JP, Mehdi S, Volk R. Cancer Detect Prev. 1990;14(3):369-75
Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus. H.T.M. Cuypers, D. Bresters, I.N. Winkel, H.W. Reesink, A.J. Weiner, M. Houghton, C.L. van der Poel and P.N. Lelie. J. Clin. Microbiol. 1992 Dec, 30(12):3220-4.1990
Reliability of polymerase chain reaction for detection of hepatitis C virus. H.L. Zaaijer, H.T.M. Cuypers, H.W. Reesink, I.N. Winkel, G. Gerken and P.N. Lelie. Lancet 1993, 341: 722-724.
Detection of HCV-RNA: A comparison of HCV-RNA assays. P.N. Lelie, H.T.M. Cuypers, M. Damen and H.L. Zaaijer. Transfusion 1994, 34.10S: S134.
PCR-pool screening, a new approach to prevent virus-transmission by window-donations. P.N. Lelie, H.T.M. Cuypers, H.L. Zaaijer, H.W. Reesink and J.G. Huisman. Vox Sang. 1994, 67.S2:0070
Comparison of methods for detection of hepatitis B virus DNA. H.L. Zaaijer, F. ter Borg, H.T.M. Cuypers, M.C.A.H. Hermus and P.N. Lelie. J. Clin. Microbiol. 1994, Sep. 32(9): 2088-91.
